Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
Open accessThe DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index.
Abstract
Breast cancer is the most frequently diagnosed cancer and the primary cause of cancer death in women worldwide. Although early diagnosis and cancer growth inhibition has significantly improved breast cancer survival rate over the years, there is a current need to develop more effective systemic treatments to prevent metastasis. One of the most commonly altered pathways driving breast cancer cell growth, survival, and motility is the PI3K/AKT/mTOR signaling cascade. In the past 30 years, a great surge of inhibitors targeting these key players has been developed at a rapid pace, leading to effective preclinical studies for cancer therapeutics. However, the central role of PI3K/AKT/mTOR signaling varies among diverse biological processes, suggesting the need for more specific and sophisticated strategies for their use in cancer therapy. In this review, we provide a perspective on the role of the PI3K signaling pathway and the most recently developed PI3K-targeting breast cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Boller, D., Doepfner, K. T., Laurentiis, A. D., Stücklin, A. G., Marinov, M., Shalaby, T., Depledge, P., Robson, A. G., Saghir, N., Hayakawa, M., et al. (2012) · PubMed · Cited by 34
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104 · cited 1×
“On the other hand, the tumor suppressor phosphatase and tensin homolog (PTEN) dephosphorylates PIP3, counteracting PI3K signaling [4] (Figure 1).”
BackgroundPalbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007 · cited 1×
“The SOLAR-1 clinical trial started to recruit the first patients during the second half of 2015, a few months after the FDA granted accelerated approval for the CDK4/6 inhibitor palbociclib in combination with endocrine treatment for postmenopausal HR+/HER2metastatic breast cancer [85,86].”
MethodThe PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749 · cited 2×
“For an extensive description of the PI3K pathway, the reader can refer to the following reviews [1,14,15].”
BackgroundInfluentialAlpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · cited 2×
“Next, a phase III SOLAR-1 clinical trial evaluated the efficacy and safety of alpelisib in combination with hormonal therapy (fulvestrant) in HR+/HER2– metastatic breast cancer patients who recurred or progressed after endocrine therapy [65].”
BackgroundResultmTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“In line with this, inhibition of both PI3K and mTOR was proposed as a good strategy to limit this compensatory mechanism [132,133].”
BackgroundThe PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism
Hoxhaj, G., & Manning, B. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0216-7 · Cited by 2,137 · cited 2×
“Several studies sug est that the PI3K/ mTOR pathway is often genetically alt i cancers [15,16].”
BackgroundComprehensive Molecular Portraits of Invasive Lobular Breast Cancer
Ciriello, G., Gatza, M. L., Beck, A. H., Wilkerson, M. D., Rhie, S. K., Pastore, A., Zhang, H., McLellan, M., Yau, C., Kandoth, C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.033 · Cited by 1,858 · cited 1×
“The most common genetic alterations of PIK3CA were observed also in metastatic breast cancer biopsies, confirming the clonal character of these mutations [19,25,26].”
BackgroundCristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
The emerging mechanisms of isoform-specific PI3K signalling
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767 · cited 1×
“Class I PI3K includes four highly homologous catalytic subunits, p110α, p110β, p110γ, and p110δ, which can associate with five regulatory subunits, collectively referred to as p85-type regulatory subunits (Figure 1) [5,6].”
BackgroundTargeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,520 · cited 1×
“PI3KCB has been shown to be responsible for the accumulation of PIP3 and reactivation of AKT in HER2-amplified breast cancers treated with a PI3KCAspecific inhibitor, and concomitant inhibition of PI3KCA and PI3KCB induces greater antitumor efficacy in HER2-amplified and PIK3CA mutant breast cancers [34].”
BackgroundInteraction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase
Simoncini, T., Hafezi-Moghadam, A., Brazil, D. P., Ley, K., Chin, W. W., & Liao, J. K. (2000) · Nature · doi:10.1038/35035131 · Cited by 1,436 · cited 1×
“Moreover, in preclinical models, the hyperactivation of the PI3K/AKT/mTOR pathway is one of the major causes of the acquired resistance to endocrine therapy through ligand-independent activation of ER by its phosphorylation, mediated by the mTOR complex 1 (mTORC1)/S6K1 axis [73,74].”
BackgroundA transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292 · cited 6×
“The second trial, PEGGY, was designed to include randomized pre- and post-menopausal Luminal A patients (HR+/HER2–) to receive paclitaxel with either pictilisib or placebo [79].”
BackgroundInfluentialA Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174 · cited 1×
“In general, pharmacological inhibition of class II can be achieved by “off-target” activities of different class I inhibitors [157], such as PIK90, PIK124, PI-103 [158], and NVP-BEZ235 [159].”
BackgroundmTOR kinase structure, mechanism and regulation
Yang, H., Rudge, D. G., Koos, J. D., Vaidialingam, B., Yang, H. J., & Pavletich, N. P. (2013) · Nature · doi:10.1038/nature12122 · Cited by 1,075 · cited 1×
“During the early developmental phases of mTOR and PI3K inhibitors, it was noted that the catalytic pocket of these two enzymes possess structural similarities, making it possible to design ATP-competitive drugs targeting both kinases simultaneously [130,131].”
BackgroundAn integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054 · cited 7×
“The second trial, PEGGY, was designed to include randomized pre- and post-menopausal Luminal A patients (HR+/HER2–) to receive paclitaxel with either pictilisib or placebo [79].”
BackgroundInfluentialTargeting the PI3K pathway in cancer: are we making headway?
Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033
Diverse somatic mutation patterns and pathway alterations in human cancers
Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., et al. (2010) · Nature · doi:10.1038/nature09208 · Cited by 1,027
PI3K/AKT signaling pathway and cancer: An updated review
Martini, M., De Santis, M. C., Braccini, L., Gulluni, F., & Hirsch, E. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.912836 · Cited by 1,020 · cited 1×
“Class II PI3Ks consist of three genes encoding for distinct functional isoforms: PI3KC2α and PI3K-C2β, which are ubiquitously expressed [2,136], and PI3K-C2γ, whose expression is mainly restricted to liver [137,138].”
BackgroundSelf-citationOverall survival with ribociclib plus endocrine therapy in breast cancer
Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903765 · Cited by 1,001 · cited 1×
“The SOLAR-1 clinical trial started to recruit the first patients during the second half of 2015, a few months after the FDA granted accelerated approval for the CDK4/6 inhibitor palbociclib in combination with endocrine treatment for postmenopausal HR+/HER2metastatic breast cancer [85,86].”
MethodMutation of the PIK3CA Gene in Ovarian and Breast Cancer
Campbell, I. G., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 916
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K. L., Winer, E. P., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy155 · Cited by 876
Saal, L. H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., Mansukhani, M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 875 · cited 1×
“The fact that PIK3CA mutations and PTEN loss are nearly mutually exclusive implies that deregulated PIP3 is critical for tumorigenesis in breast cancers and that loss of PIP3 homeostasis by abrogation of either PIK3CA or PTEN relieves selective pressure for targeting of the other gene [39].”
BackgroundHennessy, B. T., Gonzalez-Angulo, A.-M., Stemke-Hale, K., Gilcrease, M. Z., Krishnamurthy, S., Lee, J.-S., Fridlyand, J., Sahin, A., Agarwal, R., Joy, C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3441 · Cited by 874
Hudis, C. A., Barlow, W. E., Costantino, J. P., Gray, R. J., Pritchard, K. I., Chapman, J.-A. W., Sparano, J. A., Hunsberger, S., Enos, R. A., Gelber, R. D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3523 · Cited by 864 · cited 1×
“Better invasive disease-free survival (IDFS [60]), but not distant diseasefree survival (DDFS [60]) or overall survival (OS), was significantly associated with PI3KCA mutations in advanced-age, HR+, low-grade breast tumors [61].”
BackgroundMolecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837 · cited 1×
“Similarly, activating mutations in AKT1 occur in nearly 4% of Luminal [19,44], and genetic amplifications of AKT2 and PDK1 are observed in all breast cancer subtypes with a frequency of 3% and 20–38%, respectively [45,46].”
BackgroundActivation of AKT Kinases in Cancer: Implications for Therapeutic Targeting
(2005) · Advances in Cancer Research · doi:10.1016/s0065-230x(05)94002-5 · Cited by 823 · cited 1×
“Targeting of this altered pathway by pharmacologic modulation of AKT activity represents a powerful strategy for cancer intervention [110].”
BackgroundThe Akt-mTOR tango and its relevance to cancer
Hay, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.008 · Cited by 821 · cited 1×
“In line with this, inhibition of both PI3K and mTOR was proposed as a good strategy to limit this compensatory mechanism [132,133].”
BackgroundFolkes, A. J., Ahmadi, K., Alderton, W. K., Alix, S., Baker, S. J., Box, G., Chuckowree, I. S., Clarke, P. A., Depledge, P., Eccles, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800295d · Cited by 741 · cited 1×
“Pictilisib (GDC-0941; Genentech, San Francisco, CA, USA) is a pan-PI3K inhibitor showing in vitro equipotent inhibitory effects on p110α and p110δ isoforms and fewer inhibitory effects on p110β and p110γ isoforms [78] (Table S1).”
BackgroundGenomic characterization of metastatic breast cancers
Bertucci, F., Ng, C. K. Y., Patsouris, A., Droin, N., Piscuoglio, S., Carbuccia, N., Soria, J. C., Dien, A. T., Adnani, Y., Kamal, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1056-z · Cited by 713 · cited 1×
“Amplification of the PIK3CA gene locus has been also described [27], together with rare cases of PIK3CB amplification or PIK3R1 inactivating mutations [28,29].”
BackgroundBachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.-M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J.-C., Debled, M., Spaëth, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0708 · Cited by 703 · cited 1×
“In this study, a combination of everolimus and tamoxifen showed a significant reduction in cancer progression and increased overall survival rate compared to tamoxifen monotherapy [122].”
BackgroundZhou, J., Wulfkuhle, J., Zhang, H., Gu, P., Yang, Y., Deng, J., Margolick, J. B., Liotta, L. A., Petricoin, E., & Zhang, Y. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702596104 · Cited by 698 · cited 1×
“Overexpression of the PI3K-C2α encoding gene, PIK3C2A, was found in an MCF7 cancer stem-cell side population, correlating with increased tumorigenesis in mouse models [151].”
BackgroundLucas, C. L., Kuehn, H. S., Zhao, F., Niemela, J. E., Deenick, E. K., Palendira, U., Avery, D. T., Moens, L., Cannons, J. L., Biancalana, M., et al. (2014) · Nature Immunology · doi:10.1038/ni.2771 · Cited by 673
Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage
Angulo, I., Vadas, O., Garçon, F., Banham-Hall, E., Plagnol, V., Leahy, T. R., Baxendale, H., Coulter, T., Curtis, J., Wu, C., et al. (2013) · Science · doi:10.1126/science.1243292 · Cited by 636
Miller, T. W., Hennessy, B. T., González-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., García-Echeverría, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 551 · cited 3×
“The combination of alpelisib with fulvestrant also demonstrated synergism between the two drugs in xenograft models [73].”
BackgroundOncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Velculescu, V. E. (2004) · Cell Cycle · doi:10.4161/cc.3.10.1164 · Cited by 538 · cited 2×
“Dysregulation of phosphoinositide kinases, primarily in class IA PI3K, have been discovered in a number of human diseases, with mutations leading to either increased or decreased enzymatic activity being critically involved in cancer [9], developmental disorders [10], and primary immune deficiencies [11–13].”
BackgroundBaselga, J., Im, S.-A., Iwata, H., Cortés, J., De Laurentiis, M., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M., Ito, Y., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30376-5 · Cited by 533
Maira, S.-M., Pecchi, S., Huang, A., Burger, M., Knapp, M., Sterker, D., Schnell, C., Guthy, D., Nagel, T., Wiesmann, M., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0474 · Cited by 529 · cited 1×
“In vivo studies showed a marked anti-proliferative and pro-apoptotic activity towards human breast cancer cell lines with PI3K pathway alterations, sufficient to induce a dose-dependent tumor growth delay or regression in PIK3CA-mutant xenografts [75].”
BackgroundPI3K isoforms in cell signalling and vesicle trafficking
Bilanges, B., Posor, Y., & Vanhaesebroeck, B. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0129-z · Cited by 525 · cited 3×
“PIP3 also facilitates PDK1 and AKT interaction, resulting in phosphorylation of AKT at thrPhosphorylated AKT promotes protein synthesis, cell growth, and cell survival and motility by activating many downstream kinases, including the mammalian target of the rapamycin (mTOR) complex [1].”
BackgroundInfluentialSaal, L. H., Johansson, P., Holm, K., Gruvberger-Saal, S. K., She, Q.-B., Maurer, M., Koujak, S., Ferrando, A. A., Malmström, P., Memeo, L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702507104 · Cited by 520
Fritsch, C., Huang, A., Chatenay-Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D., Erdmann, D., De Pover, A., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0865 · Cited by 501 · cited 1×
“likely related to the less potent and specific inhibition of p110a compared to alpelisib, as evidenced by the higher rates of hyperglycemia in the SOLAR-1 trial compared to the SANDPIPER trial [81,91].”
ResultStructural insights into phosphoinositide 3-kinase catalysis and signalling
Walker, E. H., Perisic, O., Ried, C., Stephens, L., & Williams, R. L. (1999) · Nature · doi:10.1038/46319 · Cited by 494 · cited 1×
“During the early developmental phases of mTOR and PI3K inhibitors, it was noted that the catalytic pocket of these two enzymes possess structural similarities, making it possible to design ATP-competitive drugs targeting both kinases simultaneously [130,131].”
BackgroundPI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 476
Tabernero, J., Rojo, F., Calvo, E., Burris, H., Judson, I., Hazell, K., Martinelli, E., Cajal, S. R. Y., Jones, S., Vidal, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5482 · Cited by 474
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
Dienstmann, R., Rodon, J., Serra, V., & Tabernero, J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0639 · Cited by 462 · cited 1×
“On the other hand, a selective approach demands a precise strategy to select patients who may benefit from that treatment [80].”
BackgroundGewinner, C., Wang, Z. C., Richardson, A., Teruya-Feldstein, J., Etemadmoghadam, D., Bowtell, D., Barretina, J., Lin, W. M., Rameh, L., Salmena, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.006 · Cited by 461 · cited 1×
“In addition to PTEN, inositol polyphosphate4-phosphatase type IIB (INPP4B) can counteract PI3KCA signaling, and loss of its genetic locus has been reported in breast cancer [40,41].”
BackgroundSpatiotemporal control of endocytosis by phosphatidylinositol-3,4-bisphosphate
Posor, Y., Eichhorn-Gruenig, M., Puchkov, D., Schöneberg, J., Ullrich, A., Lampe, A., Müller, R., Zarbakhsh, S., Gulluni, F., Hirsch, E., et al. (2013) · Nature · doi:10.1038/nature12360 · Cited by 413
Self-citationPIK3CA Mutation Associates with Improved Outcome in Breast Cancer
Kalinsky, K., Jacks, L. M., Heguy, A., Patil, S., Drobnjak, M., Bhanot, U. K., Hedvat, C. V., Traina, T. A., Solit, D., Gerald, W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0632 · Cited by 401
Di Leo, A., Johnston, S., Lee, K. S., Ciruelos, E., Lønning, P. E., Janni, W., O'Regan, R., Mouret-Reynier, M.-A., Kalev, D., Egle, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30688-5 · Cited by 381 · cited 1×
“Similarly, BELLE-3 was designed to include Luminal A (HR+/HER-) breast cancer patients that had been previously unsuccessfully treated by prior endocrine therapy and mTOR inhibitors [68].”
BackgroundFrequency and spectrum of PIK3CA somatic mutations in breast cancer
Martínez-Sáez, O., Chic, N., Pascual, T., Adamo, B., Vidal, M., González-Farré, B., Sanfeliu, E., Schettini, F., Conte, B., Brasó-Maristany, F., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01284-9 · Cited by 380
Baselga, J., Cortés, J., Im, S.-A., Clark, E., Ross, G., Kiermaier, A., & Swain, S. M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.5384 · Cited by 364 · cited 2×
“In HER2+ breast cancer, mutations in PIK3CA are linked with poor prognosis not only in the advanced but also in the early setting [55,72].”
BackgroundImmunological differences between primary and metastatic breast cancer
Szekely, B., Bossuyt, V., Li, X., Wali, V. B., Patwardhan, G. A., Frederick, C., Silber, A., Park, T., Harigopal, M., Pelekanou, V., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy399 · Cited by 354 · cited 1×
“TNBC is considered the most immunogenic subtype of breast cancer, with a higher lymphocyte infiltration rate than HER2+ or HR+ tumors and thus is regarded as a promising target for immunotherapies [107].”
BackgroundThe Akt pathway in oncology therapy and beyond (Review)
Nitulescu, G., Van De Venter, M., Nitulescu, G., Ungurianu, A., Juzenas, P., Peng, Q., Olaru, O., Grădinaru, D., Tsatsakis, A., Tsoukalas, D., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4597 · Cited by 328 · cited 3×
“ity compared to other targeted approaches [109,114].”
BackgroundMosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA
Lindhurst, M. J., Parker, V. E. R., Payne, F., Sapp, J. C., Rudge, S., Harris, J., Witkowski, A. M., Zhang, Q., Groeneveld, M. P., Scott, C. E., et al. (2012) · Nature Genetics · doi:10.1038/ng.2332 · Cited by 325 · cited 2×
“Dysregulation of phosphoinositide kinases, primarily in class IA PI3K, have been discovered in a number of human diseases, with mutations leading to either increased or decreased enzymatic activity being critically involved in cancer [9], developmental disorders [10], and primary immune deficiencies [11–13].”
BackgroundOutcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
Mosele, F., Stefanovska, B., Lusque, A., Tran Dien, A., Garberis, I., Droin, N., Le Tourneau, C., Sablin, M.-P., Lacroix, L., Enrico, D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.11.006 · Cited by 314 · cited 1×
“However, PI3KCA mutations seem to have different clinical implications in advanced and metastatic breast cancer, resulting in chemotherapy resistance and poor outcome [64].”
Backgroundde Bono, J. S., De Giorgi, U., Rodrigues, D. N., Massard, C., Bracarda, S., Font, A., Arranz Arija, J. A., Shih, K. C., Radavoi, G. D., Xu, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0981 · Cited by 311 · cited 1×
“Another pan-AKT inhibitor, GDC-0068 (ipatasertib) has been used as a monotherapy in triple-negative breast cancer cases and has already entered phase I and II studies [112].”
BackgroundLópez‐Knowles, E., O'Toole, S. A., McNeil, C. M., Millar, E. K. A., Qiu, M. R., Crea, P., Daly, R. J., Musgrove, E. A., & Sutherland, R. L. (2010) · International Journal of Cancer · doi:10.1002/ijc.24831 · Cited by 302
Burke, J. E., Perisic, O., Masson, G. R., Vadas, O., & Williams, R. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205508109 · Cited by 300 · cited 1×
“Whereas mutations on the helical domain mainly rely on the loss of p85-dependet inhibitory activity, activating mutations in the catalytic subunit of p110α directly stimulate lipid kinase activity by facilitating allosteric motions required for catalysis on membranes [17].”
BackgroundKrop, I. E., Mayer, I. A., Ganju, V., Dickler, M., Johnston, S., Morales, S., Yardley, D. A., Melichar, B., Forero-Torres, A., Lee, S. C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00106-6 · Cited by 295 · cited 4×
“The second trial, PEGGY, was designed to include randomized pre- and post-menopausal Luminal A patients (HR+/HER2–) to receive paclitaxel with either pictilisib or placebo [79].”
MethodInfluentialPérez-Tenorio, G., Alkhori, L., Olsson, B., Waltersson, M. A., Nordenskjöld, B., Rutqvist, L. E., Skoog, L., & Stål, O. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1609 · Cited by 292
Lucas, C. L., Zhang, Y., Venida, A., Wang, Y., Hughes, J., McElwee, J., Butrick, M., Matthews, H., Price, S., Biancalana, M., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20141759 · Cited by 291
Somatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K Activation
Jaiswal, B. S., Janakiraman, V., Kljavin, N. M., Chaudhuri, S., Stern, H. M., Wang, W., Kan, Z., Dbouk, H. A., Peters, B. A., Waring, P., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.016 · Cited by 289 · cited 1×
“Amplification of the PIK3CA gene locus has been also described [27], together with rare cases of PIK3CB amplification or PIK3R1 inactivating mutations [28,29].”
BackgroundSelf-citationFedele, C. G., Ooms, L. M., Ho, M., Vieusseux, J., O'Toole, S. A., Millar, E. K., Lopez-Knowles, E., Sriratana, A., Gurung, R., Baglietto, L., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015245107 · Cited by 283 · cited 1×
“In addition to PTEN, inositol polyphosphate4-phosphatase type IIB (INPP4B) can counteract PI3KCA signaling, and loss of its genetic locus has been reported in breast cancer [40,41].”
BackgroundAKT in cancer: new molecular insights and advances in drug development
Mundi, P. S., Sachdev, J., McCourt, C., & Kalinsky, K. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13021 · Cited by 272 · cited 1×
“Dose-limiting side effects during treatment together with dose reduction occurred in both trials and were mainly due to the fact that the ATP-binding pocket of AKT is highly conserved among other kinases, which limits selectivity [113].”
BackgroundCiraolo, E., Iezzi, M., Marone, R., Marengo, S., Curcio, C., Costa, C., Azzolino, O., Gonella, C., Rubinetto, C., Wu, H., et al. (2008) · Science Signaling · doi:10.1126/scisignal.1161577 · Cited by 269
Self-citationComprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer
Monni, O., Bärlund, M., Mousses, S., Kononen, J., Sauter, G., Heiskanen, M., Paavola, P., Avela, K., Chen, Y., Bittner, M. L., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091582298 · Cited by 252 · cited 1×
“Conversely, activating mutations or amplification of p70S6K or KRAS are infrequent events of unknown relevance in breast cancer, compared to other types of tumors [47,48].”
BackgroundDOMIN, J., PAGES, F., VOLINIA, S., RITTENHOUSE, S. E., ZVELEBIL, M. J., STEIN, R. C., & WATERFIELD, M. D. (1997) · Biochemical Journal · doi:10.1042/bj3260139 · Cited by 251
Juric, D., Janku, F., Rodón, J., Burris, H. A., Mayer, I. A., Schuler, M., Seggewiss-Bernhardt, R., Gil-Martin, M., Middleton, M. R., Baselga, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4475 · Cited by 246 · cited 3×
“Partial or complete response was observed among 29% of pretreated metastatic breast cancer patients with PIK3CA alterations, whereas no tumor response was reported in the PIK3CA wild-type group [83].”
BackgroundInfluentialGallardo, A., Lerma, E., Escuin, D., Tibau, A., Muñoz, J., Ojeda, B., Barnadas, A., Adrover, E., Sánchez-Tejada, L., Giner, D., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.85 · Cited by 230
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials
Dey, N., De, P., & Leyland-Jones, B. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.037 · Cited by 229 · cited 1×
“Inhibitors targeting mTOR, including everolimus (RAD001), MLN0128, and AZD014, have been broadly studied and evaluated in hematological cancer and solid tumors [119] (Table S1).”
BackgroundRegulation of phosphoinositide 3-kinase expression in health and disease
Kok, K., Geering, B., & Vanhaesebroeck, B. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.01.003 · Cited by 228 · cited 1×
“Whereas p110α and p110β isoforms are ubiquitously expressed, p110δ and p110γ expression is largely restricted to hematopoietic cells [7,8].”
BackgroundLoibl, S., Majewski, I., Guarneri, V., Nekljudova, V., Holmes, E., Bria, E., Denkert, C., Schem, C., Sotiriou, C., Loi, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw197 · Cited by 227
Barok, M., Tanner, M., Köninki, K., & Isola, J. (2011) · Breast Cancer Research · doi:10.1186/bcr2868 · Cited by 226 · cited 3×
“These findings demonstrated that activation of the downstream PI3K pathway can be a possible mechanism of tumor resistance to TDM-1 [98].”
BackgroundClass IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers
Geering, B., Cutillas, P. R., Nock, G., Gharbi, S. I., & Vanhaesebroeck, B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700373104 · Cited by 225 · cited 1×
“Class I PI3K includes four highly homologous catalytic subunits, p110α, p110β, p110γ, and p110δ, which can associate with five regulatory subunits, collectively referred to as p85-type regulatory subunits (Figure 1) [5,6].”
BackgroundXing, Y., Lin, N. U., Maurer, M. A., Chen, H., Mahvash, A., Sahin, A., Akcakanat, A., Li, Y., Abramson, V., Litton, J., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1154-8 · Cited by 220 · cited 1×
“In a clinical trial (I-SPY TRIAL, NCT01277757), MK-2206 is currently tested in combination with or without trastuzumab for treatment of advanced breast cancer with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation [115].”
BackgroundPI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Stemke-Hale, K., Sahin, A., Liu, S., Barrera, J. A., Burgues, O., Lluch, A. M., Chen, H., Hortobagyi, G. N., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1089 · Cited by 219
Crowder, R. J., Phommaly, C., Tao, Y., Hoog, J., Luo, J., Perou, C. M., Parker, J. S., Miller, M. A., Huntsman, D. G., Lin, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4450 · Cited by 218 · cited 2×
“Amplification of the PIK3CA gene locus has been also described [27], together with rare cases of PIK3CB amplification or PIK3R1 inactivating mutations [28,29].”
BackgroundYoshioka, K., Yoshida, K., Cui, H., Wakayama, T., Takuwa, N., Okamoto, Y., Du, W., Qi, X., Asanuma, K., Sugihara, K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2928 · Cited by 210 · cited 1×
“Different from class I, class II PI3Ks act as monomers, regulating vesicle trafficking and membrane remodeling through their conserved N-terminal domain [2,139,140].”
BackgroundMoehler, M., Shitara, K., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., Liu, T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2296 · Cited by 208 · cited 1×
“8 months did not meet statistical significance, the absolute difference of 8 months observed between the alpelisib versus the placebo treatment was clinically relevant and valuable, with PFS benefit not only maintained but also increased in terms of overall survival outcome [84].”
BackgroundHanker, A. B., Pfefferle, A. D., Balko, J. M., Kuba, M. G., Young, C. D., Sánchez, V., Sutton, C. R., Cheng, H., Perou, C. M., Zhao, J. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303204110 · Cited by 203 · cited 1×
“Preclinical studies demonstrated that HER2 signaling largely relies on p110α rather than on other class-I PI3K isoforms [92], thus providing a strong rationale for therapeutic intervention and targeting of PIK3CA in HER2+ breast tumors.”
BackgroundFranco, I., Gulluni, F., Campa, C. C., Costa, C., Margaria, J. P., Ciraolo, E., Martini, M., Monteyne, D., De Luca, E., Germena, G., et al. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.01.022 · Cited by 197
Self-citationBarbareschi, M., Buttitta, F., Felicioni, L., Cotrupi, S., Barassi, F., Del Grammastro, M., Ferro, A., Dalla Palma, P., Galligioni, E., & Marchetti, A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0266 · Cited by 193
Martín, M., Chan, A., Dirix, L., O’Shaughnessy, J., Hegg, R., Manikhas, A., Shtivelband, M., Krivorotko, P., Batista López, N., Campone, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw562 · Cited by 180
Ndubaku, C. O., Heffron, T. P., Staben, S. T., Baumgardner, M., Blaquiere, N., Bradley, E., Bull, R., Do, S., Dotson, J., Dudley, D., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4003632 · Cited by 179 · cited 1×
“likely related to the less potent and specific inhibition of p110a compared to alpelisib, as evidenced by the higher rates of hyperglycemia in the SOLAR-1 trial compared to the SANDPIPER trial [81,91].”
ResultPI3K inhibitors: review and new strategies
Zhang, M., Jang, H., & Nussinov, R. (2020) · Chemical Science · doi:10.1039/d0sc01676d · Cited by 178 · cited 1×
“It has already shown robust activity in preclinical models of breast tumors with genetic alterations in PIK3CA [99,100].”
BackgroundBraccini, L., Ciraolo, E., Campa, C. C., Perino, A., Longo, D. L., Tibolla, G., Pregnolato, M., Cao, Y., Tassone, B., Damilano, F., et al. (2015) · Nature Communications · doi:10.1038/ncomms8400 · Cited by 177 · cited 1×
“Class II PI3Ks consist of three genes encoding for distinct functional isoforms: PI3KC2α and PI3K-C2β, which are ubiquitously expressed [2,136], and PI3K-C2γ, whose expression is mainly restricted to liver [137,138].”
BackgroundSelf-citationClass II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration
Maffucci, T., Cooke, F. T., Foster, F. M., Traer, C. J., Fry, M. J., & Falasca, M. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200408005 · Cited by 166
Clinicopathologic Analysis of Breast Cancers with PIK3CA Mutations in Japanese Women
Maruyama, N., Miyoshi, Y., Taguchi, T., Tamaki, Y., Monden, M., & Noguchi, S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0267 · Cited by 165
Juric, D., Krop, I., Ramanathan, R. K., Wilson, T. R., Ware, J. A., Sanabria Bohorquez, S. M., Savage, H. M., Sampath, D., Salphati, L., Lin, R. S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1080 · Cited by 162 · cited 1×
“An initial phase I clinical trial demonstrated clinical activity of taselisib in patients with advanced solid tumors, particularly in breast cancers with PIK3CA genetic alterations, with an overall response of 36% compared to no response in patients with wild-type PIK3CA [89].”
BackgroundZardavas, D., Marvelde, L. T., Milne, R. L., Fumagalli, D., Fountzilas, G., Kotoula, V., Razis, E. D., Papaxoinis, G., Joensuu, H., Moynahan, M. E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.8301 · Cited by 162 · cited 1×
“Better invasive disease-free survival (IDFS [60]), but not distant diseasefree survival (DDFS [60]) or overall survival (OS), was significantly associated with PI3KCA mutations in advanced-age, HR+, low-grade breast tumors [61].”
BackgroundBanerji, U., Dean, E. J., Fidalgo, J. A. P., Batist, G., Bedard, P. L., You, B., Westin, S. N., Kabos, P., Garrett, M. D., Tall, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2260 · Cited by 160 · cited 2×
“Proof-ofconcept responses were observed in patients with PIK3CA-mutant cancers treated with AZD5363 [111].”
BackgroundMethodReduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen
Shoman, N. M., Klassen, S., McFadden, A., Bickis, M., Torlakovic, E., & Chibbar, R. (2004) · Modern Pathology · doi:10.1038/modpathol.3800296 · Cited by 159
mTORC1 activity repression by late endosomal phosphatidylinositol 3,4-bisphosphate
Marat, A. L., Wallroth, A., Lo, W.-T., Müller, R., Norata, G. D., Falasca, M., Schultz, C., & Haucke, V. (2017) · Science · doi:10.1126/science.aaf8310 · Cited by 159
Rochlitz, C. F., Scott, G. K., Dodson, J. M., Liu, E., Dollbaum, C. M., Smith, H. S., & Benz, C. C. (1989) · PubMed · Cited by 157
Mouse p170 Is a Novel Phosphatidylinositol 3-Kinase Containing a C2 Domain
Virbasius, J. V., Guilherme, A., & Czech, M. P. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.23.13304 · Cited by 154
Maurer, M. S., Su, T., Saal, L. H., Koujak, S., Hopkins, B. D., Barkley, C. R., Wu, J., Nandula, S. V., Dutta, B., Xie, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0820 · Cited by 154 · cited 1×
“Similarly, activating mutations in AKT1 occur in nearly 4% of Luminal [19,44], and genetic amplifications of AKT2 and PDK1 are observed in all breast cancer subtypes with a frequency of 3% and 20–38%, respectively [45,46].”
BackgroundJain, S., Shah, A. N., Santa-Maria, C. A., Siziopikou, K. P., RADEMAKER, A. W., Helenowski, I., Cristofanilli, M., & Gradishar, W. J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4792-0 · Cited by 152 · cited 2×
“Besides pan-PI3K inhibitors, a phase I trial was conducted with the p110α-specific alpelisib inhibitor in association with trastuzumab emtansine (TDM-1) in trastuzumabresistant breast cancer patients [97].”
BackgroundLoi, S., Michiels, S., Lambrechts, D., Fumagalli, D., Claes, B., Kellokumpu‐Lehtinen, P., Bono, P., Kataja, V. V., Piccart, M. J., Joensuu, H., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt121 · Cited by 150
Dbouk, H. A., Vadas, O., Shymanets, A., Burke, J. E., Salamon, R. S., Khalil, B. D., Barrett, M. O., Waldo, G. L., Surve, C., Hsueh, C., et al. (2012) · Science Signaling · doi:10.1126/scisignal.2003264 · Cited by 148 · cited 1×
“A possible mechanism of PI3KCB activation in cancer occurs through the G protein-coupled receptor (GPCRs) [32].”
BackgroundJensen, J. D., Knoop, A. S., Lænkholm, A., Grauslund, M., Jensen, M., Santoni‐Rugiu, E., Andersson, M., & Ewertz, M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr546 · Cited by 146 · cited 1×
“In HER2+ breast cancer, mutations in PIK3CA are linked with poor prognosis not only in the advanced but also in the early setting [55,72].”
BackgroundClass II PI3K Functions in Cell Biology and Disease
Gulluni, F., De Santis, M. C., Margaria, J. P., Martini, M., & Hirsch, E. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.001 · Cited by 146 · cited 2×
“Class II PI3Ks consist of three genes encoding for distinct functional isoforms: PI3KC2α and PI3K-C2β, which are ubiquitously expressed [2,136], and PI3K-C2γ, whose expression is mainly restricted to liver [137,138].”
BackgroundSelf-citationEllis, M. J., Li, L., Crowder, R. J., Yu, T., Hoog, J., Snider, J., Davies, S. R., DeSchryver, K., Evans, D. B., Steinseifer, J., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0575-y · Cited by 141
Baselga, J., Dent, S. F., Cortés, J., Im, Y.-H., Diéras, V., Harbeck, N., Krop, I. E., Verma, S., Wilson, T. R., Jin, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.18_suppl.lba1006 · Cited by 138 · cited 2×
“Fulvestrant was administered in combination with either taselisib or placebo and the primary endpoint was the assessment of PFS in patients with PIK3CA-mutated tumors (>80% of participants) [90].”
BackgroundMethodSabine, V. S., Crozier, C., Brookes, C. L., Drake, C., Piper, T., van de Velde, C. J. �., Hasenburg, A., Kieback, D., Markopoulos, C. J., Dirix, L. Y., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.8272 · Cited by 138
Moynahan, M. E., Chen, D., He, W., Sung, P., Samoila, A., You, D., Bhatt, T., Patel, P., Ringeisen, F., Hortobagyi, G. N., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.25 · Cited by 135
Carbognin, L., Miglietta, F., Paris, I., & Dieci, M. V. (2019) · Cancers · doi:10.3390/cancers11091401 · Cited by 132
Wright, S. C. E., Vasilevski, N., Serra, V., Rodon, J. A., & Eichhorn, P. J. A. (2021) · Cancers · doi:10.3390/cancers13071538 · Cited by 124 · cited 1×
“The pan-inhibitor MK2206 remains the most prominent of the allosteric inhibitors; however, others such as TAS-117 have also shown promising effects [109,116,117].”
BackgroundTargeting PI3K in Cancer: Any Good News?
Martini, M., Ciraolo, E., Gulluni, F., & Hirsch, E. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00108 · Cited by 124
Self-citationVuylsteke, P., Huizing, M. T., Petráková, K., Roylance, R. R., Laing, R. W., Chan, S. Y. T., Abell, F., Gendreau, S. B., Rooney, I. A., Apt, D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw320 · Cited by 120 · cited 3×
“The second trial, PEGGY, was designed to include randomized pre- and post-menopausal Luminal A patients (HR+/HER2–) to receive paclitaxel with either pictilisib or placebo [79].”
MethodGulluni, F., Martini, M., Santis, M. C. D., Campa, C. C., Ghigo, A., Margaria, J. P., Ciraolo, E., Franco, I., Ala, U., Annaratone, L., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.002 · Cited by 120
Self-citationClinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women
丸山, 尚. (2009) · Cited by 119
Rab11 activity and PtdIns(3)P turnover removes recycling cargo from endosomes
Campa, C. C., Margaria, J. P., Derle, A., Giudice, M. D., Santis, M. C. D., Gozzelino, L., Copperi, F., Bosia, C., & Hirsch, E. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0086-4 · Cited by 113
Self-citationKong, D., Dan, S., Yamazaki, K., & Yamori, T. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.01.005 · Cited by 110 · cited 1×
“In general, pharmacological inhibition of class II can be achieved by “off-target” activities of different class I inhibitors [157], such as PIK90, PIK124, PI-103 [158], and NVP-BEZ235 [159].”
BackgroundEffect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2
Gnant, M., Baselga, J. M., Rugo, H. S., Noguchi, S., Burris, H. A., Piccart, M. J., Hortobágyi, G. N., Eakle, J. F., Mukai, H., Iwata, H., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt026 · Cited by 106 · cited 1×
“Everolimus and its combination with exemestane has been approved by the FDA for the treatment of hormone receptor-positive/HER2-negative (HR+/HER2−) breast cancer [120,121].”
BackgroundLoibl, S., de la Pena, L., Nekljudova, V., Zardavas, D., Michiels, S., Denkert, C., Rezai, M., Bermejo, B., Untch, M., Lee, S. C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.020 · Cited by 102 · cited 1×
“The NeoPHOEBE phase II clinical trial enrolled HER2+ early breast tumors to be treated with either buparlisib or placebo in combination with paclitaxel and trastuzumab [96].”
MethodTurner, N. C., Dent, R. A., O’Shaughnessy, J., Kim, S., Isakoff, S. J., Barrios, C. H., Saji, S., Bondarenko, I., Nowecki, Z. I., Lian, Q., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06450-x · Cited by 97
Boyault, S., Drouet, Y., Navarro, C., Bachelot, T., Lasset, C., Treilleux, I., Tabone, É., Puisieux, A., & Wang, Q. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1518-y · Cited by 91
Weisner, J., Landel, I., Reintjes, C., Uhlenbrock, N., Trajkovic-Arsic, M., Dienstbier, N., Hardick, J., Ladigan, S., Lindemann, M., Smith, S., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2861 · Cited by 91 · cited 1×
“The in vivo efficacy of borussertib was proven in combination studies with MEK-inhibitor trametinib in KRAS-mutant patientderived xenograft models, leading to a partial response [114,118].”
BackgroundSchmid, P., Zaiss, M. R., Harper-Wynne, C. L., Ferreira, M., Dubey, S., Chan, S. Y. T., Makris, A., Nemsadze, G., Brunt, A. M., Küemmel, S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2526 · Cited by 91 · cited 1×
“The trial failed to demonstrate a benefit of adding the dual mTORC1 and mTORC2 inhibitor vistusertib to fulvestrant [126].”
BackgroundPang, B., Cheng, S., Sun, S., An, C., Liu, Z., Xue, F., & Liu, G. (2014) · Scientific Reports · doi:10.1038/srep06255 · Cited by 90 · cited 1×
“PIK3CA mutations in operable primary breast cancer also indicated a significant correlation with better diseasefree survival (DFS) [62] as well as a better recurrence-free survival in the Luminal A subtype [63].”
BackgroundDomin, J., Harper, L., Aubyn, D., Wheeler, M., Florey, O., Haskard, D., Yuan, M., & Zicha, D. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20478 · Cited by 84
Katso, R. M., Pardo, O. E., Palamidessi, A., Franz, C. M., Marinov, M., De Laurentiis, A., Downward, J., Scita, G., Ridley, A. J., Waterfield, M. D., et al. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-11-1083 · Cited by 81
PI(3,4)P2 Signaling in Cancer and Metabolism
Gozzelino, L., De Santis, M. C., Gulluni, F., Hirsch, E., & Martini, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00360 · Cited by 79
Self-citationBiology of breast cancer during pregnancy using genomic profiling
Azim, H. A., Brohée, S., Peccatori, F. A., Desmedt, C., Loi, S., Lambrechts, D., Dell’Orto, P., Majjaj, S., José, V., Rotmensz, N., et al. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0111 · Cited by 78
INPP4B promotes PI3Kα-dependent late endosome formation and Wnt/β-catenin signaling in breast cancer
Rodgers, S. J., Ooms, L. M., Oorschot, V. M. J., Schittenhelm, R. B., Nguyen, E. V., Hamila, S. A., Rynkiewicz, N. K., Gurung, R., Eramo, M. J., Sriratana, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23241-6 · Cited by 78 · cited 1×
“In addition, recent findings suggest that INPP4B facilitates PI3KCA crosstalk with Wnt signaling in ER+ breast cancer via PI(3,4)P2-to-PI(3)P conversion on late endosomes, suggesting that these tumors may be targeted with combined PI3K and Wnt/β-catenin therapies [43].”
BackgroundRoyce, M., Bachelot, T., Villanueva, C., Özgüroğlu, M., Azevedo, S. J., Cruz, F. M., Debled, M., Hegg, R., Toyama, T., Falkson, C. I., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0060 · Cited by 71 · cited 1×
“Similarly, a clinical study including ER+ breast cancer patients showed that treatment with neoadjuvant letrozole and everolimus before surgery resulted in higher clinical response and reduced tumor proliferation compared to letrozole alone [123].”
ResultEssential role of class II PI3K-C2α in platelet membrane morphology
Valet, C., Chicanne, G., Séverac, C., Chaussade, C., Whitehead, M. A., Cabou, C., Gratacap, M., Gaits‐Iacovoni, F., Vanhaesebroeck, B., Payrastre, B., et al. (2015) · Blood · doi:10.1182/blood-2015-03-636670 · Cited by 71
Pistilli, B., Pluard, T., Urruticoechea, A., Farci, D., Kong, A. H., Bachelot, T., Chan, S. Y. T., Han, H. S., Jerusalem, G., Urban, P., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4596-7 · Cited by 67 · cited 1×
“Another phase Ib/II clinical trial tested the combination of buparlisib with trastuzumab in HER2+ breast tumors resistant to trastuzumab [95].”
BackgroundGuérin, M., Rezaï, K., Isambert, N., Campone, M., Autret, A., Pakradouni, J., Provansal, M., Camerlo, J., Sabatier, R., Bertucci, F., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.025 · Cited by 64 · cited 1×
“A phase I study called PIKHER2 was designed to assess the effect of combining pan-PI3K inhibitors buparlisib and lapatinib in trastuzumabresistant HER2+ metastatic breast cancer independently of PIK3CA mutational status [94].”
BackgroundCharacterization of a Tumor-Associated Activating Mutation of the p110β PI 3-Kinase
Dbouk, H. A., Khalil, B. D., Wu, H., Shymanets, A., Nürnberg, B., & Backer, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063833 · Cited by 60 · cited 2×
“The PI3KCB subunit also plays a key role in stimulating cell proliferation, invasiveness, and tumorigenesis in breast cancer [30,31].”
BackgroundFranco, I., Margaria, J. P., Santis, M. C. D., Ranghino, A., Monteyne, D., Chiaravalli, M., Pema, M., Campa, C. C., Ratto, E., Gulluni, F., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014100967 · Cited by 60 · cited 1×
“Class II PI3Ks consist of three genes encoding for distinct functional isoforms: PI3KC2α and PI3K-C2β, which are ubiquitously expressed [2,136], and PI3K-C2γ, whose expression is mainly restricted to liver [137,138].”
BackgroundSelf-citationThe INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer
Liu, H., Paddock, M. N., Wang, H., Murphy, C. J., Geck, R. C., Navarro, A. J., Wulf, G. M., Elemento, O., Haucke, V., Cantley, L. C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1262 · Cited by 59 · cited 1×
“As a consequence, loss of INPP4B prolongs both PI3K and ERK activation [42].”
BackgroundRugo, H. S., Lerebours, F., Ciruelos, E., Drullinsky, P., Ruiz Borrego, M., Neven, P., Park, Y. H., Prat, A., Bachelot, T., Juric, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.1006 · Cited by 56 · cited 3×
“To better evaluate the efficacy of alpelisib in patients treated with a CDK4/6 inhibitor, the phase II BYLieve trial was designed [87].”
BackgroundResultAutoregulation of Class II Alpha PI3K Activity by Its Lipid-Binding PX-C2 Domain Module
Wang, H., Lo, W.-T., Vujičić Žagar, A., Gulluni, F., Lehmann, M., Scapozza, L., Haucke, V., & Vadas, O. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.06.042 · Cited by 55
Self-citationSpotlight on AKT: Current Therapeutic Challenges
Landel, I., Quambusch, L., Depta, L., & Rauh, D. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00548 · Cited by 54 · cited 2×
“ity compared to other targeted approaches [109,114].”
BackgroundRegulation of p110δ PI 3-Kinase Gene Expression
Kok, K. B., Nock, G. E., Verrall, E., Mitchell, M., Hommes, D. W., Peppelenbosch, M. P., & Vanhaesebroeck, B. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005145 · Cited by 53 · cited 1×
“Whereas p110α and p110β isoforms are ubiquitously expressed, p110δ and p110γ expression is largely restricted to hematopoietic cells [7,8].”
BackgroundBraña, I., LoRusso, P. M., Baselga, J. M., Heath, E. I., Patnaik, A., Gendreau, S., Laird, A., & Papadopoulos, K. P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3030 · Cited by 51
Diverse somatic mutation patterns and pathway alterations in human cancers
Kan, Z., Jaiswal, B. S., & Seshagiri, S. (2010) · Genome biology · doi:10.1186/gb-2010-11-s1-p37 · Cited by 49
Zhang, Z., & Richmond, A. J. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.648663 · Cited by 48
Class II Phosphoinositide 3-Kinases as Novel Drug Targets
Falasca, M., Hamilton, J. R., Selvadurai, M. V., Sundaram, K., Adamska, A., & Thompson, P. E. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00963 · Cited by 46 · cited 2×
“Of note, some inhibitors, such as PI701 and PI702 [157,160], have shown to be more selective for PI3K-C2β than PI3K-C2α isoform.”
BackgroundPIK3CA mutation enrichment and quantitation from blood and tissue
Keraite, I., Garcia, V. A., García-Murillas, I., Beaney, M., Turner, N. C., Bartos, C., Oikonomidou, O., Kersaudy-Kerhoas, M., & Leslie, N. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-74086-w · Cited by 45 · cited 1×
“The most common genetic alterations of PIK3CA were observed also in metastatic breast cancer biopsies, confirming the clonal character of these mutations [19,25,26].”
BackgroundSmyth, L. M., Batist, G., Meric‐Bernstam, F., Kabos, P., Spanggaard, I., Lluch, A. M., Jhaveri, K. L., Varga, A., Wong, A., Schram, A. M., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00251-7 · Cited by 43
Chikh, A., Ferro, R., Abbott, J. J., Piñeiro, R., Buus, R., Iezzi, M., Ricci, F., Bergamaschi, D., Ostano, P., Chiorino, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7761 · Cited by 42 · cited 3×
“Different from PI3K-C2α, PI3K-C2β isoform was found to be overexpressed in human primary breast tumors and in lymph-node metastases compared to non-neoplastic breast tissue [153].”
BackgroundInfluentialBradford, L. S., Rauh-Hain, A., Clark, R. M., Groeneweg, J. W., Zhang, L., Borger, D. R., Zukerberg, L. R., Growdon, W. B., Foster, R., & Rueda, B. R. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.022 · Cited by 40 · cited 1×
“Although effects of buparlisib appeared to be synergistic with paclitaxel in preclinical and clinical models [77], during this clinical trial, the addition of buparlisib to paclitaxel did not improve PFS in the full or PI3K pathway-activated study population.”
BackgroundPapaxoinis, G., Kotoula, V., Alexopoulou, Z., Kalogeras, K. T., Zagouri, F., Timotheadou, E. T., Gogas, H. J., Pentheroudakis, G. E., Christodoulou, C., Koutras, A. K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140293 · Cited by 39
Selvadurai, M. V., Moon, M. J., Mountford, S. J., Ma, X., Zheng, Z., Jennings, I. G., Setiabakti, N. M., Iman, R. P., Brazilek, R. J., Abidin, N. A. Z., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aar8430 · Cited by 37 · cited 1×
“Interestingly, a subsequent study claimed the discovery of a PIK3-C2α-selective inhibitory molecule, MIPS-21335, suggesting a potential new therapeutic anti-thrombotic approach based on class II PI3K-selective targeting [161].”
BackgroundHong, R., Edgar, K. A., Song, K., Steven, S., Young, A. E., Hamilton, P., Arrazate, A., de la Cruz, C., Chan, C., Pang, J., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-pd4-14 · Cited by 27 · cited 2×
“Similar results were observed in xenograft models where GDC-0077 was combined with standard-of-care treatments for HR-positive breast cancer such as anti-estrogen (fulvestrant) or CDK4/6 inhibitor (palbociclib) [100].”
BackgroundResultTargeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss
Owusu‐Brackett, N., Zhao, M., Akçakanat, A., Evans, K. W., Yuca, E., Dumbrava, E. I., Jankú, F., & Meric‐Bernstam, F. (2020) · Oncotarget · doi:10.18632/oncotarget.27503 · Cited by 26
Shao, Z.-M., Liu, Y., Jiang, Y., Yu, K., & Zuo, W. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s60115 · Cited by 25 · cited 2×
“Better invasive disease-free survival (IDFS [60]), but not distant diseasefree survival (DDFS [60]) or overall survival (OS), was significantly associated with PI3KCA mutations in advanced-age, HR+, low-grade breast tumors [61].”
BackgroundPhosphoinositides in cell proliferation and metabolism
Hirsch, E., Gulluni, F., & Martini, M. (2020) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100693 · Cited by 24
Self-citationLim, B., Potter, D. A., Salkeni, M. A., Silverman, P., Haddad, T. C., Forget, F., Awada, A. H., Canon, J.-L. R., Danso, M. A., Lortholary, A. H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4131 · Cited by 19 · cited 1×
“In a phase II study (NCT02049957), sapanisertib plus exemestane or fulvestrant was well tolerated and exhibited clinical benefit in postmenopausal women with pretreated everolimus-sensitive or everolimus-resistant breast cancer [124,125].”
BackgroundMethods to Measure the Enzymatic Activity of PI3Ks
Ciraolo, E., Gulluni, F., & Hirsch, E. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-801329-8.00006-4 · Cited by 18
Self-citationUse of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer
Petrossian, K., Nguyen, D. M., Lo, C., Kanaya, N., Somlo, G., Cui, Y. X., Huang, C., & Chen, S. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4779-x · Cited by 17 · cited 1×
“In a phase II study (NCT02049957), sapanisertib plus exemestane or fulvestrant was well tolerated and exhibited clinical benefit in postmenopausal women with pretreated everolimus-sensitive or everolimus-resistant breast cancer [124,125].”
BackgroundFunakoshi, T., Latif, A., & Galsky, M. D. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.06.001 · Cited by 17
Olivero, A. G., Heffron, T. P., Baumgardner, M., Belvin, M. P., Ross, L. B., Blaquière, N., Bradley, E. K., Castanedo, G. M., Derynck, M. K., Do, S., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-ddt02-01 · Cited by 15 · cited 1×
“In particular, treatment with taselisib resulted in marked tumor suppression in preclinical studies performed on PIK3CA-mutant xenografts [88].”
BackgroundHansen, A. R., Shapiro, G. I., Do, K. T., Kumar, R., Martín-Liberal, J., Higano, C. S., Wisinski, K. B., Dean, E. J., Heath, E. I., Rathkopf, D. E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.2570 · Cited by 15 · cited 1×
“A phase I clinical trial (NCT01884285) is also studying the PI3KCB/PI3KCD inhibitor AZD8186 in patients with TNBC and known PTEN-deficient/-mutated or PIK3CB-mutated/amplified advanced tumors and in combination with abiraterone acetate or AZD2014, an mTOR inhibitor [104].”
BackgroundLoibl, S., Majewski, I., Guarneri, V., Nekljudova, V., Holmes, E., Bria, E., Denkert, C., Schem, C., Sotiriou, C., Loi, S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy536 · Cited by 15 · cited 1×
“Particularly, reduced pathological complete response (pCR) rate was linked to PIK3CA mutational status in HER+ breast cancer patients who received neoadjuvant chemotherapy and anti-HER2 therapy [93].”
BackgroundFritsch, C. M., Pfister, E., Ebel, N., Guthy, D. A., Schnell, C., & Hofmann, F. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-3934 · Cited by 14 · cited 1×
“Notably, treatment with alpelisib not only interfered with PIK3CA-mediated downstream signaling, but also induced a dose-dependent decrease in p110α protein levels in ER+/PIK3CA-mutated breast cancer cell lines [82], suggesting a dual mode of action.”
BackgroundAbstract 2160: MEN1611, a novel α-selective PI3K inhibitor in solid tumors
Merlino, G., Fiascarelli, A., Bigioni, M., Bressan, A., Irrissuto, C., Pellacani, A. U. E., Scaltriti, M., & Binaschi, M. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-2160 · Cited by 5 · cited 3×
“In HER2+ breast cancer cell lines mutated for PIK3CA, as well as in patient-derived xenograft models, MEN1611 seemed to act synergistically when associated with trastuzumab, also inducing a dose-dependent p110α protein depletion and a pro-inflammatory phenotype compatible with p110γ inhibition [103].”
BackgroundPhase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.
Wainberg, Z. A., Shapiro, G. I., Curigliano, G., Leong, S., Kristeleit, R. S., Alsina, M., Britten, C. D., Milella, M., Middleton, M. R., Olszanski, A. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.2590 · Cited by 3 · cited 1×
“Dose escalation to determine the maximum tolerated dose is still ongoing [134].”
Background
Cited by
PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
Peng, Y., Wang, Y., Zhou, C., Mei, W., & Zeng, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.819128 · Cited by 763
Signaling pathways and therapeutic interventions in gastric cancer
Lei, Z.-N., Teng, Q.-X., Tian, Q., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z.-S., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 322
Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
Gu, Y., Yang, R., Zhang, Y., Guo, M., Takehiro, K., Zhan, M., Yang, L., & Wang, H. (2025) · Molecular Biomedicine · doi:10.1186/s43556-024-00239-2 · Cited by 184
Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer
Morgos, D.-T., Stefani, C., Miricescu, D., Greabu, M., Stanciu, S., Nica, S., Stanescu-Spinu, I.-I., Balan, D. G., Balcangiu-Stroescu, A.-E., Coculescu, E.-C., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031848 · Cited by 176
“In the phosphorylated form, p-AKT, activates other targets including mTOR, promoting protein synthesis, cell growth, survival, and motility [103].”
BackgroundCurrent State and Future Challenges for PI3K Inhibitors in Cancer Therapy
Sirico, M., D’Angelo, A., Gianni, C., Casadei, C., Merloni, F., & De Giorgi, U. (2023) · Cancers · doi:10.3390/cancers15030703 · Cited by 121
Metadata
- Authors
- Li, H., Prever, L., Hirsch, E., & Gulluni, F.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-07-14
- Volume
- 13
- Issue
- 14
- Pages
- 3517
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3178774309
- Cited by
- 224
- References
- 161
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.